Bioxydyn offers MRI measurement of liver transporter fluxes using dynamic contrast-enhanced MRI (DCE-MRI) and proton density fat fraction measurements (MR-PDFF) in the investigation of liver disease, including NASH.
As the lead commercial partner in the IMI TRISTAN project that is investigating the liver and lung toxicity of many drugs in use today with the goal of validating the use of imaging biomarkers to assess and predict the toxicity of potential medicines on the liver and lungs.
Ulloa JL, Stahl S, Yates J, Woodhouse N, Kenna JG, Jones HB, Waterton JC, Hockings PD, Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. NMR Biomed. 2013 Oct;26(10):1258-70.
Banerji A, Naish JH, Watson Y, Jayson GC, Buonaccorsi GA, Parker GJ, DCE-MRI model selection for investigating disruption of microvascular function in livers with metastatic disease. J Magn Reson Imaging. 2012 Jan;35(1):196-203.
